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Melanin-concentrating hormone (MCH), a cyclic peptide hormone involved in 
energy homeostasis, is known to bind to two G protein-coupled receptors (GPCRs) in 
mammals. These receptors, melanin-concentrating hormone receptor 1 (MCHRI) and 
melanin-concentrating hormone receptor 2 (MCHR2), have been a popular target for 
MCH antagonists in an effort to fight the ongoing epidemic of obesity. In the 
presence of prolonged stimulus it is common for GPCRs to undergo rapid 
desensitization. However, the desensitization mechanisms of MCHRI and MCHR2 
are as yet poorly understood. This study aims to create epitope-tagged expression 
vectors to allow for the expression of MCHRI and MCHR2 in a tissue model. 
Utilizing a modified cell-based ELISA and fluorescence microscopy, the 
sequestration of MCHRI and MCHR2 would be measured after agonist stimulus. 
Receptor interactions with GRK2 and ~-arrestins would also be measured. The over 
expression of both MCHRI and MCHR2 proved to be cytotoxic to BHK570 cells. 
The overexpression of GRK2, ~-arrestin 1, and ~-arrestin 2 showed a relatively small 
but statistically significant increase in receptor internalization. Fluorescence 
microscopy suggests that the interaction between MCHRl and ~-arrestins were 
transient in nature. These finding suggest that MCHRI can be internalized via the 
clathrin-mediated pathway. It is likely MCH signaling is mediated a cell specific 
manner based on the cellular expression levels of GRKs and ~-arrestins. 
I 
INTRODUCTION 
Obesity 
Obesity is the accumulation of excess adipose tissue resulting in the 
impairment of one's health. Obesity has reached epidemic levels in the United States, 
with more than 61 million Americans being obese [l]. Between 1985 and 2009, there 
has been a marked increase in the prevalence of obesity in all 50 states with 12 states 
currently reporting obesity rates either equal to or greater than 30 percent [2]. In 
order to be considered obese, a person generally has to have a body mass index (BMI) 
greater than 30. A person's body mass index is calculated by dividing their weight by 
the square of their height (kg/m2) [3]. 
The underlying cause of obesity lies in the imbalance of energy intake and 
energy expenditure and can be attributed to a plethora of technological, social, and 
economic advances experienced during latter half of the 20th century as well as 
genetic predisposition. Industrial automation and mechanization has led to a 
reduction in physical exertion while the increased availability of home electronics, 
coupled ,vith lo,v cost processed foods with high caloric densities, tend to exacerbate 
already sedentary lifestyles and account for between 60 and 70 percent of obesity 
cases [ 4]. The remaining 30 to 40 percent of obesity cases can be attributed to 
genetic predisposition where it is believed that environmental factors such as a high 
fat diet and sedentary lifestyle contribute to the expression of an obese genotype [5]. 
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Obesity has been associated with increased rates of morbidity and mortality. 
Diseases and disorders showing higher rates of prevalence in obese individuals 
include coronary heart disease, stroke, hypertension, sleep apnea, osteoarthritis, 
diabetes mellitus, insulin resistance, and certain forms of cancer including colorectal 
and prostate [ 4,6]. The increased morbidity rate amongst the obese directly correlates 
with a decrease in life expectancy. Caucasian males with a BMI of greater than 35 
had a decrease in life expectancy of approximately 3 to 4 years while those with a 
BMI of 45 or greater experienced an average decrease of 9 to 12 years [7]. The 
annual obesity-related economic burden in the United States is expected to increase 
by 66 billion dollars by 2030 [8]. 
Regulation of Energy Homeostasis 
The mammalian brain regulates energy homeostasis and food intake through a 
complex system involving many neurotransmitters, signaling peptides, and feedback 
loops allowing for the maintenance of body weight to within 0.5 to I percent of an 
individual's ideal. Through the integration of multiple short term signals from 
peripheral tissues such as the liver, gastrointestinal tract, pancreas, and adipose tissue, 
the brain is able to interpret the body's nutritional state and respond to changes 
feeding patterns, physical exertion, and environmental variables such as temperature. 
These short term signals regulating energy homeostasis emanate from stretch 
receptors of the GI tract and travel to specific regions of the brain through the afferent 
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pathway of the vagus nerve while hormonal signals such as leptin and ghrelin 
influence the brain through the endocrine system [9, 1 O]. 
The regulation of energy homeostasis is achieved through the interaction of 
multiple regions of the brain ranging from the brain stem to the cortex. This is 
evident by how the visual appeal and aroma of food and an individual's 
companionship or lack thereof influences their feeding behavior. Signals from the 
various higher brain centers appear to be centrally processed by the hypothalamus. 
The hypothalamus can be divided into several anatomically distinct regions that play 
key roles in energy homeostasis. These regions include the arcuate region (ARC), 
paraventricular nucleus, and ventromedial nucleus [ 1 O]. 
The ARC of the hypothalamus acts as a central control center for feeding and 
energy homeostasis by integrating signals regarding energy homeostasis from other 
regions of the brain and body through the presence of localized semi-permeable 
capillaries. Neurons that populate the arcuate region express pro-opiomelanocortin 
(POMC), neuropeptide Y (NPY), and agouti-related peptide. The paraventricular 
nucleus is involved in the secretion of thyrotropin-releasing hormone and 
feeding signals with the hypothalamic-pituitary axis and thyroid through the 
convergence of several neuronal pathways including NPY, POMC, and galanin: an 
appetite-stimulating hormone. The ventromedial nucleus of the hypothalamus is 
involved in receiving satiety signals and is a key target for the hormone leptin: one of 
many peripheral peptides that have anorexigenic properties [9,10]. 
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Recently, several peptides or hormones have been shown to influence energy 
homeostasis resulting in a negative feedback loop. Although exact signaling cascades 
and hormonal interactions have yet to be elucidated, peripheral signals from leptin are 
known to inhibit NPY-releasing neurons in the medial hypothalamus. The decrease 
in NPY secretion results in decreasing signals to melanin-concentrating hormone 
(MCH)-secreting neurons in the lateral hypothalamus. MCH is an appetite-
stimulating hormone and a decrease in its expression results in deminished feeding 
behavior [ 11]. As leptin signaling decreases, MCH signaling increases and vice versa 
resulting in cyclical feeding patterns. 
In cases of severe or morbid obesity, it is difficult to correlate the increase of 
adipose mass solely to the strength of differential feeding signals from the brain. 
Several genetic studies of morbidly obese individuals have led to the discovery of 
mutations affecting the function of hormones or receptors involved in energy 
homeostasis. Homozygous mutations the leptin receptor gene can produce leptin 
receptors lacking a transmembrane domain and/or intracellular C-terminal tail 
inhibiting cell signaling. Mutations to the leptin peptide itself have also been 
characterized and produce a physiologically, nonfunctional hormone incapable of 
modulating MCH secretion from the hypothalamus [12]. 
GPCR 
Many hormones involved in energy homeostasis, such as ghrelin, NPY, 
orexin, galanin, and MCH trigger cellular and systemic changes through the binding 
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of G protein-coupled receptors (GPCRs) [9]. While GPCRs show relatively little 
sequence homology amongst themselves, being classified into over 100 subfamilies, 
their general structure is highly conserved [13]. The core of a GPCR is composed of 
7 hydrophobic transmembrane domains, 3 extracellular loops, 3 to 4 intracellular 
loops, an extracellular amino terminus and in many cases an intracellular carboxyl 
terminal tail. The extracellular loops are important in ligand binding and the N-
terminus plays an important role in stabilizing the binding of larger signaling peptides 
and glycoproteins. Amino acid residues on the intracellular loops and the C-terminal 
tail are important for the binding of heterotrimeric G proteins and for the interaction 
of proteins involved in desensitization and internalization [ 13]. 
GPCR signaling is initiated by the binding of its ligand to the extracellular 
binding pocket through Vanderwaal's interactions. The binding of the ligand causes 
either a conformational shift within the GPCR or acts to stabilize the GPCR 
conformation. stabilization or conformational shift allows interactions between 
the second and third intracellular loops as well as domains near the distal end of the 
C-terminal tail to interact with the G protein causing its activation [14,15]. 
G Proteins 
s bind and activate G proteins. Heterotrimeric G proteins are made up 
of three subunits, alpha (a), beta(~), and gamma (y) and generally act to regulate 
gene transcription. To date, no less than 20 Ga subunits, 6 G~ subunits and 11 Gy 
subunits have been identified [ 16]. In the inactive state, all three subunits are 
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associated in the trimeric form with guanosine diphosphate (GDP) bound to the Ga 
subunit. Once activated through interaction with GPCRs, the G protein conformation 
is altered allowing for the release of GDP and the binding of guanosine triphosphate 
(OTP), activating the G protein and causing the dissociation of the Ga and G0y 
subunits [ 16]. 
Some of the most extensively characterized G proteins include Gas, Gau0 , and 
Gaq. The Gq protein can activate phospholipase C (PLC) resulting in 
phosphotidylinositol-4,- bisphosphate (PIP2) being cleaved into diacylglycerol 
(DAG) and inositol-1,4,5-triphosphate (IP3). The IP3 induces the release of 
intracellular calcium stores from the endoplasmic reticulum while the DAG functions 
to activate protein kinase C (PKC) which phosphorylates Ras resulting in the 
activation of the mitogen-activated protein kinase (MAPK) pathway. The Gs protein 
activates protein kinase A (PKA) through the stimulation of adenylyl cyclase, which 
subsequeny increases cyclic AMP concentrations. The 0 0 protein activates the 
MAPK pathway in a similar manner to the Gq protein while the Gi protein inhibits the 
activation of adenylyl cyclase [16, 17]. 
Desensitization 
The desensitization of GPCR signaling helps to modulate receptor activity. 
There are several different types of receptor desensitization but the two most common 
are homologous desensitization, which is dependent on the GPCR being activated, 
and heterologous desensitization, which is a receptor activation-independent pathway 
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commonly mediated through a second messenger regulated kinase [ 18]. The general 
mechanism for desensitization includes the uncoupling of the G-protein from the 
GPCR which is usually due to receptor phosphorylation. The phosphorylation event 
is then followed by receptor endocytosis. Once internalized, the receptors can either 
be degraded or recycled back the cell membrane [ 19]. Specialized enzymes and 
proteins, such as GPCR kinases, 0-arrestins, and clathrin are commonly implicated in 
playing important roles in the rapid desensitization of GPCR's [18]. Other methods 
of GPCR desensitization have also been characterized or proposed including 
internalization of receptors through lipid rafts or by changes in receptor conformation 
that terminate signaling in an endocytosis independent manner [20,21]. 
G Protein-Coupled Receptor Kinases 
G-protein coupled receptor kinases (GRK's) are a family of kinases that 
phosphorylate serine and threonine residues located on the 3rd intracellular loops and 
C-terminal tails of GPCR's [22]. There are seven known members of the GRK family 
with all members showing a significant level of sequence homology in the substrate 
recognizing N-terminal domain, membrane targeting C-terminal domain; and 
centrally located catalytic domain [23]. The GRKs can be broken down based on 
functional similarity and tissue specificity with GRK 1 and 7 expressed primarily in 
the visual tract, GRK 4 generally expressed in the testes, and GRK 2,3,5 and 6 
ubiquitously expressed throughout the body [23]. GRK 2 has been widely 
characterized through the study of the phosphorylization of the 02 adrenergic receptor 
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and it has been shown to phosphorylate a number of different GPCR's in an agonist-
dependent manner [24]. 
p -arrestins 
P-arrestins are a family of proteins that recognize activated GPCR' s through 
their conformation and phosphorylated serine and threonine residues [25]. There are 
currently four known arrestins divided into two families: visual arrestins and B-
arrestins. The visual arrestin family is almost exclusively expressed in the retina and 
consists of arrestin 1 and arrestin 4 [ 18]. The B-arrestin family is ubiquitously 
expressed at varying levels throughout the body and consists of arrestin 2 CB -arrestin 
1) and -arrestin 3 CB -arrestin 2) [26]. At least two splice variants of B -arrestin 1 and 
B -arrestin 2 have been identified including a variant of B -arrestin 1 with insertions of 
8 amino acids and a variant of B -arrestin 2 with an insertion of 11 amino acids and it 
is hypothesized that these variants may bind to different families of GPCR's [27,28]. 
The B -arrestins are involved in GPCR desensitization in two distinct ways; 
through the inhibition of G-protein activation by binding to the activated GPCR and 
clathrin. It has been shown that arrestins will preferentially bind GRK 
phosphorylated GPCR's compared to native receptor with the B2 adrenergic receptor 
showing a 10 to 30 fold increase in affinity [29]. G protein-coupled receptors can be 
classified into either class A or class B receptors based on their affinity for binding 
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either~ -arrestin 1 or~ -arrestin 2. This affinity is conferred through differential 
sequence on the receptor's C-terminal tail [30]. 
Class A receptors include the ~2 adrenergic receptor, µ-opioid receptor, and 
the Dopamine DIA receptor. Receptors that belong to this class show a higher affinity 
for binding ~ -arrestin 2 rather than ~ -arrestin 1. In the class A model of receptors, 
the interaction between the receptor and ~-arrestin 2 is transient in nature with the ~ -
arrestin 2 dissociating from the receptor immediately after receptor localization in 
clathrin-coated pits [31]. Class B receptors include thyrotropin-releasing hormone 
receptor, neurokinin NKl receptor, and the neurotensin 1 receptor. These receptors 
have been shown to have equal binding affinity for both ~ -arrestin 2 and ~-arrestin 1 
and the ability to bind visual arrestin [26]. Class B receptors exhibited stable 
interactions with arrestins with both the receptor and the~ -arrestins co-localizing to 
endosomes. Class B receptors also resensitize and recycle back to the plasma 
membrane less rapidly than Class A receptors [31]. 
Melanin-concentrating Hormone 
l\1elanin-concentrating hormone (I\1CH) \Vas originally discovered in teleost 
fish where it functions to aggregate melanosomes in the fish's scales resulting in a 
lightening of skin color [32]. In mammals, MCH is a highly conserved neuropeptide 
consisting of a cyclic 19 amino acid chain with a single disulfide bond between amino 
acids 7 and 16 [33]. MCH has been shown to act as an orexigenic peptide, inducing 
energy conservation as well as increasing one's hunger sensations [3 3]. Recent 
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studies have identified several additional physiological effects of MCH; these include 
the regulation of sleep cycles, voiding behaviors, and possibly involvement in the 
regulation of depression[34-36]. Neurons which express MCH are solely expressed 
in the areas of the central nervous system associated with energy homeostasis: the 
lateral hypothalamus and zona incerta [3 7]. 
Melanin-concentrating Hormone Receptor 
Melanin-concentrating hormone binds and activates two known receptors: 
melanin-concentrating hormone receptor 1 (MCHRl) and melanin-concentrating 
hormone receptor 2 (MCHR2). MCHRl was originally identified as the orphan G 
protein-coupled receptor SLC-1 through the isolation and characterization of its 
ligand MCH [38]. MCHRl consists of 353 amino acid residues with its encoding 
gene located on human chromosome 22 at 22ql3.3 and is highly conserved across 
humans, mice, and rats [33]. MCHRl mRNA has been identified in multiple regions 
of the brain including the olfactory tubercle, hippocampus, amygdala, thalamus, 
ventromedial and dorsalmedial nuclei of the hypothalamus, which is consistent with it 
being involved energy regulation. MCHRl is capable of binding several different 
heterotrimeric G proteins including Gu0 and Gq (Figure 1) allowing it diverse 
signaling pathways [39]. The second MCH receptor, MCHR2 consists of 340 amino 
acid residues and exhibits a 38 percent sequence homology with MCHRl. The gene 
encoding for MCHR2 is found on human chromosome 6 at 6q21 [40,41]. MCHR2 
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MCHRl MCHR2 
\ 
~ an~~•v=J~ 
intracellular calcium, ERK 1h, and inhibition of PKA 
respectively. MCHR2 signals only through the Gq pathway. 
mRNA is also widely expressed in the brain including the precentral gyrus, 
hippocampus, amygdala, putamen, and the caudate nucleus, thalamus, corpus 
callosum, and medulla oblongata, and hypothalamus. MCHR2 has been shown to 
primarily couple to only Gq heterotrimeric G proteins most likely due to significant 
sequence divergence of the 2nd and 3rd intracellular loops compared to MCHRl [41]. 
Leptin 
Leptin is a peptide hormone involved in modulating energy homeostasis. 
Leptin was discovered in 1994 by Friedman and colleagues and indirectly plays an 
important role in the regulation of adipose tissue mass [ 42]. Leptin mRNA, which is 
transcribed by adipose cells, is 4.5 kb long and encodes a peptide consisting of 167 
amino acids. The hormone targets leptin receptors in the hypothalamus where it 
functions to regulate energy homeostasis. Homozygous mutations of leptin or its 
receptor have been shown to reduce energy expenditure and produce severe obese 
phenotypes in mice [ 42,43]. Genetic screening of families exhibiting early onset 
morbid obesity has also identified mutations in the human leptin receptor gene of 
afflicted family members [ 44]. 
MCHModels 
The role of MCH in energy homeostasis has been examined using several 
model systems. A study by Qu et al. identified a significant up-regulation of MCH 
mRNA expression in the hypothalamus of leptin-knockout mice compared to controls 
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indicating a potential role for MCH in mediating energy homeostasis [ 45]. 
Additional studies involving the injection of MCH into the hypothalamus of 
rats further supported this hypothesis by showing a marked increase in feeding 
activity of the satiated rats [ 46]. In further studies utilizing a transgenic mouse model 
(MCH-OE) over expressing MCH in the hypothalamus, Ludwig et al. observed that 
MCH-OE mice were hyperphagic and exhibited an increase of adipose tissue 31 % 
greater than that of control mice when fed a high fat diet while homozygous MCH 
knockout mice were shown to be hypophagic and lean compared to controls and 
exhibited increased energy expenditure at rest [ 4 7 ,48]. 
Chen et al. created a line of MCHRl knockout mice where the MCHRl gene 
was excised through homologous recombination. Studies utilizing this line of mice 
have shown an increase in resistance to diet-induced obesity and hyperphagia 
compared to wild-type mice fed a similar diet [49]. Mutations of the MCHRl gene 
have also been examined in European populations. These epidemiological studies of 
German children and young adults exhibiting early-onset obesity have identified 
several single nucleotide polymorphisms (SNPs) in the MCHRl gene that are not 
present in the control population [50]. Compared to MCHRl, there is relatively little 
known about MCHR2 due to the fact that MCHR2 isn't natively expressed in rodents 
[ 51]. However, Ghoussaini et al. performed a genetic study on French children 
exhibiting an obese phenotype, comparing the genetic sequence of their MCHR2 gene 
to the sequence of average weight controls. While the study couldn't directly link 
any of the SNPs identified as a direct cause of obesity, it did identify one that could 
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potentially mediate overeating behavior in children [52]. Recently, MCH receptors 
have been targeted by small molecule antagonists as a treatment of obesity and as of 
late 2007, there were no less than 97 patent applications under review [53]. Animal 
models utilizing antagonists generally resulted in reduced food intake coupled with a 
decrease in body mass which was usually due to a decrease in adipose tissue however 
human trials had yet to be conducted [53]. 
Significance 
Obesity has reached epidemic levels in the United States. More than 61 
million Americans are considered obese and this number is expected to grow into the 
coming decades. Recent studies have implicated MCH signaling through MCHRl as 
a target to potentially treat obesity with several MCHR antagonists currently under 
development. However, relatively little is known about the desensitization 
mechanisms of MCHRl and even less about MCHR2 since it's not natively expressed 
in rodents. The first aim was to clone both MCHRl and MCHR2 into N-terminal and 
C-terminal mammalian expression vectors. This was accomplished utilizing genetic 
cloning techniques and could potentially allow for the measurement of agonist-
induced internalization of MCHRl and MCHR2 in a cultured cell model. Both the 
second aim was to determine the interaction between MCHRl, ~ -arrestin 1, and ~ -
arrestin 2 while the third aim was to determine what role GRK2 had in the regulation 
of receptor desensitization and internalization. The second and third aims were 
accomplished by cotransfection of MCHRl and either ~ -arrestins or GRK2 and 
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quantifying internalization utilizing a modified cell-based ELISA to measure receptor 
desensitization and fluorescence microscopy to measure receptor colocalization. 
Enhancing the understanding of MCHR desensitization and internalization will 
hopefully allow for better treatment options to fight the growing obesity epidemic. 
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MATERIALS AND METHODS 
PCR 
Polymerase chain reaction was performed using the following primers: 
MCHRl up primer, MCHR2 up primer, MCHR1&2 down primer. One hundred 
microliter reactions were utilized to facilitate PCR purification. MCHRl/2 template 
was prepared and 1 Ong was pipetted into a sterile PCR tube. A PCR master mix was 
prepared by pipetting 3 µl each of 1 OµM up and down primers into a microfuge tube 
along with 20µ1 of 5X GC buffer, 6µ1 of2.5mM dNTP's, 2µ1 ofHIFI Taq polymerase 
and 64µ1 of sterile water on ice. The master mix was added to the template in the 
PCR tube and amplified. Products were verified by running 5 to 1 Oµl on a 1 % 
agarose gel. 
PCR Purification 
Prior to enzymatic manipulation, PCR products were purified using either a 
Qiagen or Bio Basic PCR purification kit following the manufacturers recommended 
protocol. DNA was resuspended in 30µ1 of elution buffer (2mM Tris-HCL pH 
8.0~8.5) and stored at -20°C. 
Restriction Digestion 
Restriction enzyme (RE) digests were performed with a 40µ1 total volume. A 
volume of 5µ1 of DNA was added to a sterile microfuge tube. A master mix was 
prepared by pipetting 4µ1 of 1 OX RE buffer into a microfuge tube along with 1.5µls 
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of the appropriate enzyme(s) (Promega, New England Biolabs). Sterile water was 
added to a final volume of 35µls. The master mix was added to the DNA and the 
digest was incubated for a minimum of 5 hours at 37°C. The digests were then frozen 
at -20°C. DNA loading buffer was added just prior to gel loading to a final 
concentration of 1 X. 
Agarose Gel Purification 
Plasmid samples with DNA loading buffer were run on a 1 % T AE agarose gel 
along with a DNA molecular weight standard (Fisher) until DNA bands were well 
separated. A small metal spatula was used to perforate the gel. DNA filter paper, pre 
wet with IX TAE, was inserted into the perforations and the DNA was run on to the 
filter paper under low voltage. Ultraviolet light was used to verify DNA was present 
on the filter paper. The filter paper was then removed from the gel and spun down in 
a microfuge tube to remove the DNA. The presence of DNA was verified by placing 
the microfuge tubes into an ultraviolet light box. 
Ligation 
Ligations were performed by adding 3 µl of RE digested and gel purified 
plasmid and 6µ1 of RE digested and gel purified receptor PCR product to sterile 
microfuge tubes. To the tubes, a master mix containing 2µ1 of T4 ligase buffer, 1 µl of 
T 4 ligase (Fisher), and 11 µl of sterile water was added. The ligation mixture was then 
incubated at 13 ° C overnight. 
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Preparation of Calcium Competent E. coli 
A 100ml culture of DH5a E. coli was incubated in LB in an orbital incubator 
at 37°C until cells were in mid-log phase (0.5 0.7 OD@ 600nm). The culture was 
then chilled on ice and centrifuged in a SS-34 rotor at 7000RPM for 7 minutes at 4°C 
prior to decanting the supernatant. The E. coli were resuspended in 10ml of sterile 
O. IM CaCh solution and incubated for 20 minutes on ice. The cells were then 
centrifuged and decanted as above prior to being resuspended in 5ml of 0.1 M 
CaCh/15% glycerol solution. Microfuge tubes with 200µ1 aliquots were frozen and 
stored at -80°C. 
P:repa:ration of Electrocompetent E. coli 
A 100ml culture of DH5a E. coli in LB was incubated in an orbital incubator 
at 37°C until cells were in mid-log phase (0.5 - 0.7 OD 600nm). The culture was 
then chilled on ice and centrifuged at 7000 rpm for 7 minutes at 4°C in an SS-24 rotor 
prior to decanting the supernatant. The E. coli was washed with 1 volume of sterile 
dH20, 1/2 volume of sterile dH20 and 1120th volume sterile 10% glycerol 
respectively, centrifuging and decanting as previously described between each step. 
The coli was then resuspended in 11500th volume sterile 10% glycerol solution 
before 40µ1 volumes were aliquoted into microfuge tubes. The aliquots were then 
frozen and stored at -80°C. (Note: all wash steps were performed on ice.) 
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Calcium Competent E. coli Transformation 
Two hundred microliter aliquots of calcium competent E. coli were thawed on 
ice (as prepared or courtesy of Dr. Rey Sia). Five microliters of plasmid ligation was 
then added. The aliquots were incubated on ice for 30 minutes, heat shocked for 90 
seconds at 42°C water bath and then incubated on ice for 2 minutes. Nine hundred 
micro liters of LB was then added to the aliquots prior to incubation in an orbital 
incubator at 37°C for 1 hour. One hundred microliter, 10 microliter, and 1 microliter 
volumes of E. coli were plated on LB plus 1 OOµg/ml ampicillin agar plates and 
incubated overnight at 37°C. 
Electroporation of coli 
Electrocompetent E. coli were thawed on ice. One microliter of plasmid was 
added and the aliquots were incubated on ice for 2 minutes. The E. coli were 
transferred to an ice-cold Electroporation cuvette and electroporated at l .52kv for 6 
milliseconds. The coli was resuspended in 1 ml of LB broth, transferred to a sterile 
microfuge tube and incubated in an orbital incubator at 37°C for 1 hour. One hundred 
micro liter, 10 microliter, and 1 microliter volumes of E. coli were plated on LB plus 
1 OOµg/ml ampicillin (Fisher) agar plates and incubated overnight at 3 TC. 
Plasmid Miniprep 
Culture tubes containing 5 ml of broth with 1 OOµg per ml ampicillin was 
inoculated with a single E. coli colony from LB amp plates. The cultures were 
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incubated in an orbital shaking incubator overnight at 37°C. Plasmid DNA was 
extracted following the recommended Qiagen or Bio Basic Miniprep protocol. 
Plasmid Maxiprep 
Culture tubes containing 5 ml of LB broth with 1 OOµg per ml ampicillin was 
inoculated with a single E. coli colony from LB amp plates. The cultures were 
incubated in an orbital shaking incubator for 6 to 8 hours at 37°C. The cultures were 
then used to inoculate 500ml LB cultures with 1 OO~tg per ml ampicillin which were 
incubated overnight in an orbital shaking incubated at 37°C. Plasmid DNA was 
extracted following the recommended Qiagen Maxiprep protocol. 
Tissue Culture 
BHK-570 cells (ATCC) were cultured as a tissue monolayer using DMEM-
media (CellGro) containing 10% fetal bovine serum (FBS) (Atlanta Biological). 
Cells were fed every four days and passaged when they were confluent. Culture 
conditions were set at 37°C, 5% CO2, and 80% humidity. 
Transfection 
Cell lines were transfected at 90% confluency for ELISA experiments and 
50% confluency for fluorescence microscopy experiments. Transfections were 
carried out following the recommended protocol from SignaGen utilizing their 
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LipoD293 reagent. Media was changed 5 hours post- transfection and experiments 
were run approximately 48 hours post transfection. 
Fixed Cell Fluorescence Microscopy 
Coverslips seeded with BHK-570 cells were transfected with MCHRl-VSV g 
( courtesy of G. Milligan) ± ~-arrestin 1 or 2 ( courtesy of R. Lefkowitz) or± GRK 2 
or GRK2 K220L ( courtesy of G. Milligan). Coverslips seeded with BHK-570 cells 
were transfected with MCHRl-VSV g ± ~-arrestin 1 or 2. Cells were then incubated 
for approximately 24 hours prior to MCH treatment, then treated± 1 µM MCH 
(American Peptide) for time points of 0, 2, 5, 10, 20, and 30 minutes. The coverslips 
were then rinsed 2 times with ice-cold PBS before fixing for 10 minutes in 4% 
paraformaldehyde at room temperature. The coverslips were then rinsed 3 times with 
PBS before being transferred to a humidification chamber and incubated in blocking 
buffer for 1 hour. The coverslips were then incubated for 1 hour with rabbit anti-
VSV g polyclonal antibodies (Sigma) at 1 :50 in blocking buffer. The coverslips were 
then washed 3 times with PBS before being treated with (Roche) at 1 : 5 00 and 
AlexaFluor goat anti rabbit secondary antibody (Invitrogen) at 1 :250 in blocking 
buffer for 1 hour. The coverslips were then washed 3 times in PBS before being 
mounted on slides with Prolong Gold (Invitrogen). The edges of the coverslips were 
sealed with clear nail polish. Fluorescence micrographs were obtained with a Zeiss 
Axioskop fluorescence microscope with a Zeiss Axiocam camera and Zeiss 
Axiovision software. 
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Live Cell Fluorescence Microscopy 
Coverslips seeded with BHK-570 cells were transfected with MCHRl-VSVg 
± ~-arrestin 1 or 2 or± GRK 2 or GRK2 K220L. Cells were then incubated for 
approximately 24 hours prior to MCH treatment. Coverslips were rinsed twice with 
HBSS preheated to 37°C. Coverslips were then mounted in a Sykes-Moore chamber. 
MCH was added at 1 µM in HBSS (CellGro) and fluorescence micro graphs were 
taken from time point Oto 30 minutes using a Nikon inverted fluorescence 
microscope utilizing a SPOT camera and software. 
Cell Based ELISA 
Twenty-four well plates were seeded with BHK-570 cells and transfected with 
MCHRl-VSVg ± ~--arrestin 1 or 2 or± GRK 2 or GRK2 K220L. Twenty-four hours 
post-transfection, the plates were aspirated and incubated at room temperature in 
labeling buffer with 1: 1000 mouse anti VSV g (Sigma) for 2 hours. The plates were 
then washed2 times in labeling buffer before being treated with MCH at 0, 15, and 
30 minute time points. The plates were then washed 1 time with ice cold PBS before 
being fixed in 1% p:m1formnldehy<le for ?.O mlnntes 8t room temp. The plates were 
then washed 2 times with PBS for 5 minutes before being incubated with goat anti-
mouse HRP-conjugated secondary antibody (Bio-Rad) in PBS plus 5% goat serum 
for 45 minutes. The plates were then washed 3 times with PBS for 5 minutes prior to 
added 175µ1 of POD blue (Roche). The plates were incubated were incubated for 3 
minutes on an orbital shaker before being neutralized with 17 5 µI of 10% sulfuric acid 
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solution. One hundred fifty microliters from each well was transferred to a 96 well 
plate and the absorbance was read at 450nm using a Synergy 1 or ELx800 plate 
reader (BioTek). 
Statistical Analysis 
The averages of the data were reported± the standard error of the mean 
(SEM). Student's t-test was performed to determine statistical significance with data 
scoring equal to or greater than the 95th percentile considered significant. 
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RESULTS 
Designing a Strategy to Epitope Tag MCHRl and MCHR2 
Melanin-concentrating hormone (MCH), a cyclic polypeptide containing 19 
amino acid residues, has been shown to play an integral role in regulating energy 
homeostasis. Previous studies utilizing knockout mice lacking MCH have produced 
mice with a lean phenotype, which also exhibit increased level of activity and reduced 
stores of adipose tissue. In these same studies, mice overexpressing MCH tend to be 
resistant to insulin and express an obese phenotype. In upper mammals, such as 
primates and humans, MCH can signal through two different GPCR's: MCHRl and 
MCHR2, which share 38% sequence homology. MCHRl has been shown to activate 
multiple signaling pathways through the activation of Gq, Gi, and 0 0 proteins while 
MCHR2 is only known to activate the Gq pathway. While MCHRl has been widely 
studied, far less is understood about MCHR2, in part because it is not natively 
expressed in rodent model systems such as or rats. 
To further the understanding of the function of MCHR2, both individually and 
in coordination with MCHRl in the same cell, we decided to clone both MCHRl and 
MCHR2 into tagged mammalian expression vectors. use of epitope-tagged 
expression vectors allowed for the ability to utilize several different experimental 
techniques, such as western blots, immunostaining, and cell-based ELISA's to study 
the receptor's behavior. The transient transfection nature of the plasmids also 
allowed for the study of the receptors behavior in multiple types of cells. Different 
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types of cells can behave differently based on the expression of endogenous proteins 
involved in receptor regulation and internalization [54]. 
To create the vectors, N-terminal MYC- and HA-tagged mammalian 
expression plasmids were obtained from Clontech (Figure 2) and human MCHRI or 
human MCHR2 cDNA were cloned into their multiple cloning sites. Direct excision 
of the MCHRI pcDNA3 and MCHR2 pcDNA3 cDNA and subsequent ligation into 
the MYC and HA plasmids proved not feasible due to a reading frame shift between 
plasmids. In order to modify the MCHRI and MCHR2 cDNA to correct for this 
reading frame shift, PCR up primers were designed with an EcoRI restriction enzyme 
site upstream of the MCHRI and MCHR2 coding regions and PCR down primers 
containing a Xhol restriction enzyme site downstream of the cDNA. The PCR 
primers (Appendix 1) were designed to delete the stop codons and have similar 
annealing temperatures while still being specific to their targets and contained 
restriction enzyme digestion sequences in the correct reading frame. The PCR was 
carried out following the program listed in the materials and methods section. 
Fallowing the completion reaction, a small sample of the products were run 
on a 1 percent Ti\.E agarose gel \Vith ethidium bromide for approximately 30 minutes 
at 100 volts to verify the product. The DNA would be intercalated with ethidium 
bromide and therefore glow under ultraviolet light. band of 1294 bp was expected 
for MCHRI while a band of 1044 bp was expected for MCHR2. As illustrated in 
Figure 3, MCHRI, located in lane 2, produced a band of 1300 bp which was 
approximately what was expected. An additional band was located 
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Figure 3: Agarose gel electrophoresis of MCHRl & MCHR2 PCR 
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near 800 base pairs and is most likely due to non specific primer binding due to sub-
optimal annealing temperatures. The MCHR2 sample located in lane 3 produced a 
band of 1025 bp which was consistent with what was expected; the receptor cDNA's 
were now in the appropriate reading frame for the intended target plasmids. 
To facilitate the insertion of the reading frame-modified MCHRland MCHR2 
cDNA into the pCMV MYC and pCMV HA vectors, a restriction enzyme digest was 
performed followed by gel purification. MCHRl and MCHR2 PCR cDNA along 
with pCMV MYC and pCMV HA maxiprep DNA (Figure 4) were digested with 
EcoRl and Xhol restriction enzymes for 5 hours at 37°C. The digested samples were 
then separated by agarose gel electrophoresis to allow for purification according to 
the gel purification procedure in the methods section. Five micro liter aliquots of the 
plasmid restriction enzyme digests were separated by agarose gel electrophoresis to 
verify the bands were approximately the correct length. Single digests containing 
either EcoRl or Xhol enzymes were expected to produce DNA bands at 3782 base 
pairs for the pCMV HA plasmid and 3791 base pairs for the pCMV MYC plasmid. 
Double digests containing both EcoRl and Xho 1 enzymes were expected to cut out a 
21 base pair section of the polylinker and produce DNi\ bands of 3761 base pairs for 
the pCMV plasmid and 3 770 base pairs for the pCMV MYC plasmid. 
illustrated in Figure undigested pCMV and pCMV MYC (lanes 2 
and 6 respectively) show bands near 2 kilobases which was expected because the 
plasmids were in a supercoiled conformation and would therefore travel further on the 
gel. Single enzyme digests of pCMV HA (lanes 7 and 8) as well as pCMV MYC 
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(lanes 2 and 3) show bands just under 4 kilobases which was expected while the 
double digests (lane 5 MYC and lane 9 HA) also show bands just smaller than 4 kilo-
bases which was also expected since a 31 base pair excision would be insufficient to 
cause a visible shift on the gel. Gel purification was verified by illuminating the 
purified DNA via ethidium bromide and long wave ultraviolet light. 
The gel purified MCHRI and MCHR2 cDNA was then ligated into the gel-
purified pCMV HA and pCMV MYC plasmids as described in the materials and 
methods section (Figure 5). Receptor cDNA was added to plasmid DNA along with 
T4 DNA ligase and incubated overnight at 13 °C to generate 4 expression vectors: 
pCMV HA MCHRl, pCMV MYC MCHRl, pCMV HA MCHR2, and pCMV MYC 
MCHR2. The T4 DNA ligase was heat-deactivated at 70°C for 10 minutes before 
aliquots of ligation mixture were used to transform DH5a E. coli. Transformed E. 
coli were selected for on LB plus ampicillin agar plates before being miniprepped. 
The miniprep DNA was then subjected to digestion with EcoR 1 and Xho 1 to 
verify successful insert ligation through separation by agarose gel electrophoresis. 
Two DNA bands were expected each digest. As illustrated with 6, double 
MCHRl (bottom gel, lanes 3 and 6) produced bands of just 
under 4 kilobases and between 1.5 and 1.0 kilobases in length while double digestion 
of pCMV HA MCHR2 (bottom gel, lanes 9 and 12) produced bands of just under 4 
kilobases and just larger than 1.0 kilobases in length which is what was expected if 
ligation was successful. Results for pCMV MYC MCHRl and pCMV MYC 
MCHR2 were similar (top gel, lanes 3, 6, 9, and 12 respectively). 
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While restriction enzyme digestion verified MCHRl and MCHR2 ligation 
into pCMV HA and pCMV MYC; it could not confirm that the DNA sequence 
remained intact. So in order to verify that a small point mutation or insertion or 
deletion had not occurred that could alter experimental results, genetic sequencing 
was performed. Clone DNA plasmid preps were subjected to DNA sequencing using 
sequencing primers (Appendix 1) to verify the sequences for MCHRl and MCHR2 
were intact and in frame. Sequencing results indicated that the cDNA for all 4 clones, 
pCMV HA MCHRl, pCMV MYC MCHRI, pCMV HA MCHR2, and pCMV MYC 
MCHR2 was correct. 
In order to test for the plasmids surface protein expression, BHK cells were 
transiently transfected with pCMV HA MCHRI, pCMV MYC MCHRl, pCMV HA 
MCHR2, and pCMV MYC MCHR2. Cells were then fixed and immunostained using 
MYC- and HA-tag specific primary antibodies and fluorescent secondary antibodies 
and DAPI before being imaged with a fluorescent microscope. Observation of the 
cells 24 hours post transfection showed they exhibited a spherical cell morphology in 
contrast to the nontransfected cell's spiky morphology. These observations indicated 
the cells were not in a homeostatic state. Fluorescent micrographs indicated limited-
to-no surface expression of both MCHRI or MCHR2 with either tag. The lack of 
expression coupled with the change in cell morphology indicates that the expression 
vectors may have been cytotoxic to the cells. The cytotoxicity could be due to several 
factors including protein folding, tag size, and or tag sequence which will be 
expanded upon in the discussion section. 
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Designing a Strategy to Tag MCHRl and MCHR2 with Fluorescent Proteins. 
Since the N-terminal epitope tagging of both MCHRI and MCHR2 proved 
unsuccessful, we next decided to utilize C-terminal monomeric red and green 
fluorescent protein expression vectors to answer questions about co-localization and 
internalization through fluorescence microscopy. The use of the C-terminal 
fluorescent tags would help prevent any possible interference of the tag during protein 
folding. An enhanced yellow fluorescent protein C-terminal expression vector 
containing MCHRI cDNA, obtained from Graeme Milligan's lab, had been shown to 
be successfully expressed post-transfection in both BHK and CHO cells based on 
experiments performed in our lab. 
The cloning procedure was almost identical to the cloning of the MYC- and 
HA-tagged plasmids. To create the vectors, C-terminal GFP- and monomeric RFP-
tagged mammalian expression plasmids were obtained from Clontech (Figure 7) and 
Human MCHRland MCHR2 cDNA was cloned into a multiple cloning site. In order 
to modify the MCHRI and MCHR2 cDNA to be in the correct reading frame to ligate 
into the vectors, PCR up primers were designed with a NheI restriction enzyme site 
upstream of the MCHRl and MCHR2 coding regions and PCR down primers 
containing a XhoI restriction enzyme site downstream of the cDNA. PCR 
primers (Appendix 1) were designed to delete the stop codons and have similar 
annealing temperatures while still being specific to their targets and contained 
restriction enzyme digestion sequences in the correct reading frame. The PCR was 
carried out following the program listed in the materials and methods section. 
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After completion of the PCR cycle, small samples of the products were 
analyzed via agarose gel electrophoresis to verify the band sizes. A band of 1294 
base pairs was expected for MCHRl while a band of 1044 base pairs was expected 
for MCHR2. As illustrated in Figure 8, MCHRl, located in lane 2, produced a band 
1330 bp which was approximately what was expected. The MCHR2 sample loaded 
in lane 3 produced a band near 1065bp which was consistent with what was expected; 
the receptor cDNAs were now in the appropriate reading frame for the intended target 
plasmids. 
To facilitate the insertion of the reading frame modified MCHRland MCHR2 
cDNA into the pAcGFPl-Nl and pDsRed-Monomer-Hyg-Nl vectors, a restriction 
enzyme digest was performed followed by gel purification. MCHRl and MCHR2 
PCR cDNA along with the pDsRed-Monomer-Hyg-Nl maxiprep DNA were digested 
with Nhel and Xhol restriction enzymes for 5 hours at 37°C. The digested samples 
were then separated by agarose gel electrophoresis to allow for purification according 
to the gel purification procedure in the methods section. Five microliter aliquots of 
the plasmid restriction enzyme digests were separated by agarose gel electrophoresis 
to verify the bands were approximately the correct length. Double digests containing 
both Nhe 1 and Xho 1 enzymes were expected cut out a base pair section of the 
polylinker and produce a DNA band of 5726 base pairs for pDsRed-Monomer-
Hyg-Nl plasmid. As illustrated in Figure 7, the double digests of 5 clones of 
pDsRed-Mnomer-Hyg-Nlshowed bands just smaller than 6 kb which was expected 
since a 22 base pair excision would be insufficient to cause a visible shift on gel 
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(Figure 9). Gel purification was verified by illuminating the purified DNA via 
ethidium bromide and long wave ultraviolet light. 
The gel purified MCHRl and MCHR2 cDNA was then ligated into the gel-
purified pAcGFPl-Nl and pDsRed-Monomer-Hyg-Nl vectors as described 
previously to generate 4 expression vectors: pAcGFPl-Nl MCHRI, pDsRed-
Monomer-Hyg-Nl MCHRI, pAcGFPI-Nl MCHR2, and pDsRed-Mnomer-Hyg-Nl 
MCHR2. Aliquots of the ligation mixtures were used to transform calcium 
competent DH5a E. coli. Transformed E. coli were selected for on LB+ amp agar 
plates at 37°C overnight. Examination of the plates after incubation revealed no 
colonies indicating the possibility of incomplete RE digestion prior to ligation. 
ELISA Optimization 
Little is currently known about the desensitization of MCHRl in response to 
agonist treatment. However, a paper published by N. Evans, et.al, in 2001, measured 
recruitment and internalization of stably-expressing MCHRl HEK293 cells 
cotransfected with GRK2, and 0 -arrestin 1 or 2. Their results indicated that MCHRI 
recruited 0 -arrestin 2 at a preferentially higher rate than~ -arrestin 1. Internalization 
assays showed that neither the overexpression of B -arrestin I and B -arrestin 2 
resulted in internalization of either B-arrestin. They hypothesized this was a result of 
the B -arrestin dissociating from the receptor during early stages of receptor 
internalization [55]. While this paper showed that B -arrestin 2 co-localized with 
MCHRl, it didn't explicitly measure changes in the rate of MCHRI internalization 
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from the cell surface. In another paper by Y. Saito, et.al, published in 2004 and 
which utilized MCHRl-Flag stably expressing HEK293 cells, over expression of wild 
type ~ -arrestin 2 had no effect on the internalization of MCHRl, but transfection of 
dominant negative ~ -arrestin 2 (284-409) reduced receptor internalization by nearly 
40 percent. Similar to the Evans et.al paper, ~ -arrestin 1 transfection showed little 
effect on the internalization of MCHRl [56]. The inhibition ofMCHRl 
internalization with cotransfection of dominant negative ~ -arrestin 2 seems to point 
towards a clathrin-mediated endocytosis event. However, cotransfection with wild 
type ~-arrestin 2 did not increase receptor internalization as expected if~ -arrestin 2 
played a function in desensitization, thus contradicting the papers earlier statement. 
In order to measure the percent of MCHRI internalized from the cell surface, 
a modified Cell-based ELISA was developed. In an experiment performed by Scott 
Portwood, CHO cells stably expressing VSVg-MCHR-1 were grown in a 12 weli 
plate and incubated with rabbit anti-VSV g antibody in HBSS on ice for 2 hours. One 
~LM MCH in F12k- media was added over a 30 minute time course prior to fixation 
with 4% paraformaldehyde for 10 minutes. The plate was then blocked with RIPA 
buffer vvith 5% goat serum and for 20 minutes at room temperature. Goat anti-rabbit 
secondary antibody was added in RIP A buffer with 5% goat serum for 1 hour 
prior to the addition of POD blue. The reaction was stopped by the addition of 10% 
sulfuric acid and the absorbance was read at 405nm. The results indicated that 100 
percent of MCHRl was internalized from the cell surface after approximately 40 
minutes of MCH treatment. To verify the results, a control experiment was 
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performed minus MCH and the same results were observed [57]. The percent surface 
receptor measured without MCH treatment fell to zero after 40 minutes which 
indicated that the assay didn't function as it should and wasn't measuring receptor 
internalization but rather the primary antibody falling off the receptors on the surface 
of the cells. 
In order to effectively and accurately measure VSV g-MCHRI internalization 
following agonist treatment, several different modifications to the ELISA methods 
were explored. Initially, BHK570 cells transfected with VSV g were plated in 24 well 
plates. Cells were treated with 1 µM MCH for either 0, 15, or 30 minutes and then 
incubated with rabbit anti VSV g antibody in a 5% milk PBS solution for 20 minutes 
on ice before fixing with 2% paraformaldehyde for 10 minutes on ice. Cells were 
then treated with goat anti rabbit HRP secondary antibody in PBS for 40 minutes 
prior to the addition of POD blue substrate and reading the absorbance at 450 nm 
using a 96 well plate reader. results revealed that the signal from the BHK cells 
expressing VSV g was nearly equal to that of the background signal of the control 
BHK-VSV g tagged cells not treated with primary antibody. 
order to try and boost the signal to background ratio several alterations to 
these methods were performed. Multiple fixation methods were performed by 
changing the concentration of paraformaldehyde from 2% to 4% as well as increasing 
the fixation time from 10 minutes to 20 minutes which resulted in no significant 
increase in the assay signal. Fixation followed by primary antibody incubation was 
also attempted utilizing blocking buffer consisting of 5% milk in RIPA buffer for 20 
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minutes followed by VSV g antibody in blocking buffer for 90 minutes. As before, 
there was no appreciable signal present above background. Species of primary 
antibody was also tested by utilizing both mouse anti-VSVg and rabbit anti-VSVg 
along with the appropriate HRP conjugated goat secondary antibodies. Experimental 
results for both species were consistent with one another, but again showed no 
appreciable signal over background. 
A modified cell based ELISA technique developed by the Hinkle lab at the 
University of Rochester was also tested [58]. This technique involved incubating the 
cells with mouse anti-VSVg primary antibody at room temperature prior to half the 
cells being treated with MCH while the other half was treated with just vehicle at 0, 
15, and 30 minute time points. The cells were then fixed with 3% paraformaldehyde 
prior to the addition of secondary antibody (Figure I 0). A total of 6 experiments 
were performed using BHK570 cells cotransfected with VSV g-tagged MCHRl and a 
GFP plasmid. Each experiment had a triplicate set of wells for each time point± 
MCH resulting in 18 individual samples. The results from all six experiments were 
averaged and normalized prior to plotting. Results from the experiments indicated 
the plasma membrane in the absence of MCH with percent receptor at the O minute 
time point 100% ± 2.3%, the 15 minute time point 103% ± 2.3%, and the 30 minute 
time point 96% ± 2. 7%. Cellular exposure to MCH resulted in small but marked 
decrease in the concentration of surface receptor with percent 
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Figure 11: MCHRl is Sequestered from the Plasma Membrane Under 
Agonist Exposure. B) The loss of MCHR I from the plasma membrane 
was measured using the modified cell based ELISA protocol. MCH treated 
BHK.570 cells exhibited lose of VSVg-MCHR I from the cell surface over 
30 minutes. Cells treated with vehicle showed no internali zation. 
receptor at the O minute time point 100% ± 2.2%, the 15 minute time point 94% ± 
2.2%, and the 30 minute time point 85% ± 2.5% (Figure 11 ). 
Role of ~-arrestin 1 and 2 in Regulating the Internalization of MCHRl 
By successfully designing a Cell-based ELISA protocol to measure agonist-
induced VSV g-MCHRl internalization by measuring the concentration ofreceptor on 
the plasma membrane during prolonged agonist treatment, we were now able to 
address the question of whether MCHRI was internalized by a clathrin-mediated 
method. Clathrin-mediated endocytosis has been shown to regulate the 
desensitization of a multitude of different GPCRs [ 18] but the affinity of MCHRI to 
this type of internalization has yet to be studied in detail. Clathrin-mediated 
endocytosis follows a relatively conserved pathway where the C-terminal tail of the 
GPCR is phosphorylated, usually by GRKs and sometimes secondary messengers 
such as PKC. The B -arrestins then bind to the phosphorylated tail and interact with 
clathrin heavy chain to facilitate receptor endocytosis [ 18]. 
The over expression of B -arrestin has been shown to increase GPCR 
internalization [59] and it was hypothesized that~ -arrestin vvould act increase the 
rate of MCHRI internalization. To measure the effect 0 -arrestin had on MCHRI 
internalization, BHK cells were cotransfected with VSV g-MCHRI and either 0 
arrestin 1 or 0 -arrestin 2 in 24-well plates. The ELISA protocol was performed as 
described above and in the materials and methods. A total of 7 experiments were 
performed using BHK570 cells cotransfected with VSV g-tagged MCHRI and GFP 
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tagged ~ -arrestin 1 and a total of 5 experiments were performed using BHK570 cells 
cotransfected with VSV g tagged MCHRl and GFP tagged ~ -arrestin 2. Like the 
control, each experiment had a triplicate set of wells for each time point± MCH. The 
results from the ~ -arrestin experiments were averaged and normalized prior to 
plotting. 
The ~ -arrestin 1 experiment indicated the level of MCHRl on the plasma 
membrane of BHK570 cells decline with and without the addition of agonist. 
Without the addition of hormone, the percentage of receptor localized to the plasma 
membrane equaled 100% ± 3 .4%, after 15 minutes the percentage of receptor on the 
membrane fell to 92% ± 2.6%, and after 30 minutes the percentage receptor fell to 
79% ± 2.2%. Treatment with MCH resulted in a significant decrease in the 
concentration of surface receptor with percentage of receptor on the plasma 
membrane equaling 100% ± 2.2%, after 15 minute of agonist exposure it equaled 
88% ± 2.9%, and after 30 minutes of exposure it equaled 64% ± 2.4%, (Figure 12). 
The increase in receptor internalization would be expected with the addition of 
hormone if MCHRl is internalized through clathrin-mediated endocytosis while the 
internalization 'Nithout the addition of MCH seems to indicate hormone-independent 
basal internalization. 
Results from the ~ -arrestin 2 experiments were similar to that of the ~ -
arrestin 1 experiment in regard to internalization of MCHRl post treatment with 
MCH. The level of MCHRl on the plasma membrane of BHK570 cotransfected with 
VSV g MCHRl and GFP ~ -arrestin 2 declined with the addition of MCH with the 
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Figure 12: Transient cotransfection of ~-arrestin l increases the loss of 
MCHRJ from the cell surface over time. BHK570 cell were tran fected 
with VSVG-MCHRI and either p arrestin I or p arrestin . el ls were 
treated with MCH or vehicle over a 30 minute time course and 
internalization was measured utilizing a modifi ed cell-based ELI A. ~ 
arrestin I increases the loss of MCHRJ from the plasma membrane in both 
a agonist dependent and agonist independent manner. Ave ± SEM plotted. 
percent of receptor on the cells surface 100% ± 6.5% after initial hormone treatment, 
after 15 minutes agonist exposure, surface receptor fell to 83% ± 4.6%, and following 
30 minutes of hormone exposure, surface receptor declined to 62% ± 4.0%. 
Treatment with placebo resulted in no significant change in the concentration of 
MCHRl localized to the plasma membrane with the percentage of receptor at the 
cells surface being 100% ± 4.0%, 103% ± 5.7%, and 97% ± 4.5% following 0, 15, 
and 30 minutes agonist exposure respectively (Figure 13). 
Receptor internalization was compared between the control, ~ -arrestin 1, and 
~ -arrestin 2 experiments for the 30 minute time point. Statistical analysis was 
performed utilizing Student's t-test to determine if ~-arrestin lor ~-arrestin 2 
significantly influenced receptor internalization. Cotransfection of MCHRl and~ -
arrestin 1 resulted in an agonist independent net loss of 17.0% of MCHRl from the 
plasma membrane (p<0.005) and an agonist-dependent net loss of 21.1 %. The 
cotransfection of~ -arrestin 2 resulted in no appreciable agonist-independent net loss 
and an agonist-dependent net loss of 24.7% (p<0.01) (Figure 14). Based, the increase 
in receptor internalization would be expected with the addition of MCH if lS 
internalized through clathrin-mediated endocytosis. 
ofGRK2 
G protein-coupled receptor kinase 2 is a family member of a group of protein 
kinases that generally function to regulate GPCR signaling through the 
phosphorylation of serine and threonine residues located on the third intracellular 
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Figure 13: Transient cotransfection of P-arrestin 2 increases the loss of 
MCHRl from the cell surface over time. BHK570 cells wer tran fectcd 
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loop and C-terminal tail of GPCR' s. The addition of phosphate groups to these areas 
has been shown to terminate signaling by inhibiting G protein binding and to help 
facilitate receptor internalization by increasing the affinity of~ -arrestin. A mutant 
form of GRK2, GRK2 K220R, has also been characterized. This dominant negative 
form of GRK2 is known to knock down the expression of wild type GRK2 when co-
expressed. Based on previous studies [60], it was hypothesized that the over 
expression of GRK2 would increase the rate of MCHRl internalization while 
transfection with GRK2 K220R would knock down endogenous GRK 2 expression 
resulting in MCHRl internalization being greatly inhibited. ELISAs to measure 
receptor internalization were performed using the same method as those with ~ -
arrestin. 
The GRK2 results indicated the level of MCHRl on the plasma membrane of 
BHK570 cells decline both with and without the addition of agonist. Without the 
addition of hormone, the percentage of receptor localized to the plasma membrane 
equaled 100% ± 8. 8%, after 15 minutes the percentage of receptor on the membrane 
remained relatively the same at 107% ± 10.3%, and after 30 minutes the percentage 
receptor fell to 91 % ± 9.7%. Treatment with MCH decreased in concentration of 
surface receptor with percentage of receptor on the plasma membrane equaling 100% 
± 11.4 %, after 15 minute of agonist exposure, the level of surface receptor decreased 
to 91 % 11.6%, and after 30 minutes of exposure it fell to 79% ± 9.7%, (Figure 15). 
The agonist-induced internalization results for GRK 2, though less pronounced, were 
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Figure 15: Transient cotransfection GRK2 increases the loss of 
MCHRl from the cell surface over time. BHK570 ce ll s were transfcc ted 
with YSYG MCHR I and either GRK2 or dominant negati ve GRK2 . Cell 
were treated with MCH or vehicle over a 30 minute time course and 
internalization was measured utili zing a modified cell based I I A. 
GRK.2 increases the loss of MCHR I from the plasma membrane in both a 
agonist dependent and agonist independent manner although at a lower 
level than P arrest in . Ave ± SEM plotted. 
similar to those of cells cotransfected with B -arrestin 2. The level of surface receptor 
on the plasma membrane of control cells remained stable at approximately 100 
percent until the 30 minute time point where it fell to 90.5 percent. The results point 
toward an intermediary reaction of GRK 2 between both endogenous B -arrestin 1 and 
B -arrestin 2 with the agonist-dependent internalization being mediated through B -
arrestin 1 and B -arrestin 2 while the agonist-independent internalization being solely 
mediated through B -arrestin 1. 
The dominant-negative GRK 2 results indicated the level of MCHRl on the 
plasma membrane ofBHK570 cells remained relatively constant over time both with 
and without the addition of agonist. Without agonist addition, the percentage of 
receptor localized to the plasma membrane equaled 100% ± 3.4%, at 15 minutes, the 
percentage of receptor on the membrane was 101 % ± 2.4%, and after 30 minutes the 
percentage receptor was to 89% ± 2.4%. The percent surface receptor after the 
addition of agonist was 100% ± 4.9 %, after 15 minute of agonist exposure, the level 
of surface receptor was 106% ± 4.5%, and after 30 minutes of exposure it was 97% ± 
5 .1 %, (Figure 16). The agonist-independent internalization values from the dominant 
negative GRK 2 studies were similar to those of the control remaining relatively 
constant near 100%. However, agonist treatment showed a decrease in the amount of 
MCHRl being internalized post agonist treatment as would have been expected. 
Receptor internalization was also compared between the control, GRK2, and 
dominant-negative GRK2 experiments for the 30 minute time point and tested to 
determine if the significantly influenced receptor internalization as previously 
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Figure 16: Transient cotransfection GRK2 but not dominant negative 
GRK2 increases the loss of MCHRl from the cell surface over time. 
BHK570 cells were transfected with VSVG MCHRI and either GRK2 or 
dominant negati ve GRK2 . Cell s were treated with MC H or vehicle over a 
30 minute time course and internali zation was measured utili zing a 
modified cell based ELISA. Dominant negati ve GRK.2 inhibits the los 
of MCHRl from the plasma membrane in response to agoni st. Ave SEM 
plotted. 
described. Cotransfection of MCHRl and GRK2 resulted in no appreciable agonist-
independent net loss and an agonist-dependent net loss of 6.5% (p<0.005). The 
cotransfection of dominant negative GRK2 again resulted in no appreciable agonist-
independent net loss of receptor but revealed an agonist-dependent MCHRl net gain 
of 11.3% (p<0.005) on the plasma membrane (Figure 17). 
Characterizing the interaction between MCHRl, p -arrestin 1, and p -arrestin 2 
G protein-coupled receptors can be divided into two classes. Class A 
receptors preferentially bind 0 -arrestin 2 over 0 -arrestin 1 and their interaction is 
transient in nature with 0 -arrestin and the receptor dissociating prior to entering the 
endosome. Class B receptors have equal affinity for both 0 -arrestin 1 and ~ -arrestin 
2 and form stable interactions resulting in the translocation of both receptor and 0 -
arrestin into the endosome [31]. To characterize the interaction between MCHRl, 0 -
arrestin 1, and 0 -arrestin 2, BHK570 cells split on coverslips were co-transfected 
with both VSV g-MCHRl and GFP ~-arrestin. Cells were treated with agonist for 30 
min, fixed, permeabilized, and stained with VSV g and AlexaFluor red fluorescent 
secondary antibody before observation under a fluorescent microscope at 1 OOx 
magnification. 
In cells cotransfected with VSV g-MCHRI and~ -arrestin 1, in the absence of 
hormone, the MCHRl fluorescence is evenly distributed across the surface of the 
plasma membrane while the 0 -arrestin 1 fluorescence exhibits an even distribution 
throughout the cytoplasm. Cells fixed after 30 minutes of hormone treatment 
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exhibited distinct red fluorescent foci on the plasma membrane representing 
aggregation of MCHRl. Observation of the GFP tagged B -arrestin 1 revealed that it 
had remained distributed throughout the cytoplasm with evidence of weak interaction 
through the observation of co localized fluorescence with the MCHRl (Figure 18). 
Cells cotransfected with VSV g-MCHRl and B -arrestin 2 produced similar results 
with only a weak interaction between MCHRI and B -arrestin 2 being observed 
(Figure 19). There was no indication that either B -arrestin 1 or B -arrestin 2 were 
internalized with MCHRI suggesting that MCHRI is a class A receptor since their 
interactions were transient in nature which is consistent with previous findings [55]. 
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Figure 18: The interaction between VSVg MCHRJ and p arrcstin I 
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Figure 19: The interaction between VSVg MCHR1 and p arrcstin I 
and 2 are transient in nature. BHK 570 cell s plit on co er lip were 
transfected with VSVG MCHRI and GFP ~ arre ti n 2. ell s wer treat d 
with hormone or vehicle, fixed and the V V g MCHR I wa 
immunostained. Cells treated with vehicle express ven GFP ~ arrc. tin 
fluorescence throughout the cyto ol while VSVG M HR I is present at the 
plasma membrane. Cells treated with MCH show recruitment of FP ~ 
arrestin to the plasma membrane but no evidence of internali zation . 
Experiment performed by Katrina Haude. 
DISCUSSION 
Obesity has reached epidemic levels in the United States with greater than 61 
million Americans being defined as obese [1]. Obese individuals with a BMI of 45 or 
greater can expect to lose up to 12 years of their life expectancy [7]. The recent 
increase in the prevalence of obesity can partially be attributed to the increase of 
leisure time, decrease in physical exertion, and high fat diets [ 4]. It's hypothesized 
that these environmental factors could contribute to the expression of certain genes 
increasing the likelihood of an obese phenotype [5]. 
The mammalian brain regulates energy homeostasis through a complex 
signaling system [9, 1 O]. One of the hormones of this system, MCH has been shown 
to help regulate energy homeostasis through MCHRl-mediated signal transduction 
pathways via both MCH and MCHRl knockout mouse models [ 49, 50]. Regulation 
of the MCH signaling pathway has been implicated as a potential obesity treatment 
through the modulation of MCHRl yet little is definitively known about its 
desensitization [55]. In humans and other upper mammals, a second MCH receptor 
has been identified. However, little is currently known about MCHR2 primarily since 
it isn't natively expressed in rodents [53]. 
In order to further the understanding of both MCHRl and MCHR2 as 
potential therapeutic targets to obesity, we decided to create epitope-tagged 
expression vectors. The creation of these vectors would allow for the transient 
expression of MCHRl, MCHR2, and the transient co-expression of MCHRl and 
MCHR2 in BHK570 cell models to test for co-localization on the plasma membrane, 
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to characterize the desensitization of both following agonist treatment, and to 
determine the roles~ -arrestinl, ~ -arrestin 2, and GRK2 had in receptor endocytosis. 
Several N-terminal epitope-tagged MCHRl vectors, utilizing FLAG and VSV g tags 
had been previously constructed with positive results [56,61]. 
Ideally, mammalian expression vectors should have several features including 
a high expression level in transfected cells and a highly immunoreactive tag [62]. 
The pCMV-Myc and pCMV-HA vectors utilized for cloning had a Cytomegalovirus 
promoter driving transcription, allowing for constitutive protein expression and a high 
copy number allowing for up to 500 plasmids in each individual transfected cell to 
further boost protein expression. The c-Myc and Hemagglutinin (HA) tags featured 
by the plasmids were both highly immunoreactive and well-characterized tags 
allowing for a high signal to background noise ratio in multiple assays including, 
ELISAs, fluorescence microscopy, and western blotting, while the small physical size 
of the tags shouldn't interfere with the function of MCHRl or MCHR2 [63]. 
The apparent cytotoxicity of the pCMV-HA MCHRl, pCMV-MYC MCHRl, 
pCMV-HA MCHR2, and pCMV-MYC MCHR2 plasmids in BHK cells and the 
subsequent lack of expression could potentially be attributed to several factors 
including the expression level and copy number of the plasmid as well as the 
alteration of the proteins structure expressed by the plasmid. The pCMV-Myc and 
pCMV-HA vectors both had a copy number of 500 meaning that the average 
transfected cell had approximately 500 copies of the plasmid within its nucleus. The 
plasmids also utilized a cytomegalovirus promoter that drove transcription in a 
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constitutive manner. The transcription and translation machinery of the transfected 
cell is utilized to produce the recombinant protein from the plasmid as well as the 
standard contingent of proteins normally expressed by the cell. It's possible that the 
combination of copy number and constitutive expression of the plasmids overtaxed 
the cellular machinery resulting in insufficient expression of endogenous protein 
within the cell creating a cytotoxic environment. 
As an alternative, MCHRl and MCHR2 could be cloned into mammalian 
expression vectors exhibiting inducible promoters. Inducible promoters can be turned 
on or off by either chemical means, such as antibiotics, steroids, and metals or 
physical means, such as light exposure or temperature variations. The use of 
plasmids with inducible promoters allows for the regulation of where and when the 
cloned cDNA would be expressed. A common inducible promoter utilized in 
mammalian expression vectors utilizes the antibiotic tetracycline to regulate 
transcription allowing for not only the regulation of when the cloned gene is 
transcribed but also how strongly the cloned gene is transcribed since transcription 
would be dependent on tetracycline concentration. By cloning MCHRl and MCHR2 
into such a vector it would be possible to optimize the expression level of the receptor 
in a temporal manner as well as modulate their cellular concentration [ 64]. 
Alterations in protein confirmation may also induce cell cytotoxicity. The 
pCMV-Myc and pCMV-HA vectors both utilized N-terminal epitope tags. The N-
terminus of G protein-coupled receptors has been shown to play a role in receptor 
signaling through stabilization of ligand binding. The addition of an immunoreactive 
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tag to the N-terminal, however small, could potentially interfere with ligand signaling 
resulting in either the prevention of receptor activation in the presence of hormone or 
constitutive activation of the receptor in the absence of hormone. Protein structure is 
based on the sequence of amino acids found in the protein. The secondary structure 
of a protein is formed starting at the amino or N-terminal of the peptide, continuing to 
fold as it works its way to the C-terminal [ 65]. The addition of a small polypeptide 
tag to the N-terminal of MCHRl and MCHR2 could have potentially altered its 
conformation. It's possible that a conformational change to the protein could make it 
cytotoxic to the cell. A conformational change could interfere with chaperone 
binding resulting in an excess accumulation of receptor in intracellular compartments 
such as the ER. 
Whether the pCMV-HA MCHRl, pCMV-MYC MCHRl, pCMV-HA 
MCHR2, and pCMV-MYC MCHR2 induced cell cytotoxicity was a result of protein 
misfolding due to the N-terminal tags or simply the over expression of the 
recombinant protein, characterizing the localization and desensitization of MCHRl 
and MCHR2 proved not feasible with the pCMV-Myc and pCMV-HA vectors. As an 
alternative method, we utilized pAcGFPl-Nl and pDsRed-Monomer-Hyg-Nl 
terminal tagged vectors. The use of C-terminal tagged vectors would eliminate the 
potential for N-terminal tag interference with protein folding and our lab as well as 
others had previously utilized an e YFP-tagged MCHRl vector that was successfully 
expressed in both BHK570, CHO-Kl, and HEk293 cell lines [66]. 
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The cloning process of the pAcGFPl-Nl and pDsRed-Monomer-Hyg-NlC-
terminal tagged vectors involved selecting for the plasmids by plating on agar pates 
with the appropriate antibiotic at the appropriate concentration. Following incubation 
with ampicillin at a concentration of I OOµg/ml, only colonies of pDsRed-Monomer-
Hyg-Nl were visibly present. One possibility why no pAcGFPl-Nlplasmid colonies 
were present was that the transformation of E. coli with the pAcGFPl-Nlplasmid was 
faulted in some way, creating E. coli clones that were not resistant. This theory was 
quickly discounted by performing several further transformations. Upon further 
examination of the literature, it was clear that the reason no pAcGFPl-Nlplasmid 
colonies were present on amp plates was simply because the pAcGFPl-Nlplasmid 
had a neomycin resistance and not the ampicillin gene originally thought. 
While trying to determine the reason for the failure of the pAcGFP 1-
Nl plasmid cloning, the process of constructing the MCHRl and MCHR2 pDsRed-
Monomer-Hyg-Nl constructs continued. The MCHRI and MCHR2 cDNA 
engineered without their stop codons were successfully digested with EcoRl and Xho 
I and gel purified along with the pAcGFPl-Nl plasmid, allowing for their ligation. 
Following ligation, the recombinant vectors were transformed into coli and plated 
on agar plus ampicillin for selection. Unfortunately, there were no colonies present 
on the plates. The transformation process was repeated several times using both 
electrocompetent and calcium competent cells with the same null results indicating 
that the transformation step wasn't likely the cause of the failure. The RE digest 
utilized two restriction enzymes; EcoRl and Xho 1. It is possible that the vector or 
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cDNAs were only cut by one or the other nuclease and not both simultaneously. If 
this were the case, during the ligation process, only one side of the cDNA would be 
successfully joined to the vector. The subsequent recombinant vector would be linear 
in conformation instead of circular and this would have resulted in its targeted 
degradation when transformed into its host. 
Another possibility was that the DNA ligase was inactive or its ligase buffer 
contents were degraded. In order for DNA to be ligated, a high energy 
phosphoanhydride bond has to be formed. The DNA ligase utilizes ATP as the 
energy source for this reaction. Adenosine triphosphate is highly instable and can 
readily be hydrolyzed into inorganic phosphate and ADP was exposed to temperature. 
It is possible the ligase buffer had undergone too many freeze and thaw cycles 
resulting in the breakdown of the ATP it contained. It is also possible that the DNA 
ligase itself may have gone bad. In order for proteins to function properly, they must 
maintain the correct 3 dimensional confirmation. The conformation of proteins is 
dependent on their primary sequence and it is affected by changes in pH, temperature, 
or the exposure to reducing agents. It is possible that pipette cross contamination 
could have introduced a reducing agent to the ligase causing its structural breakdown. 
ELISA Optimization 
The desensitization of G protein-coupled receptors can be performed through 
the use of an ELISA as well as many other methods including flow cytometry and 
fluorescence microscopy [ 56, 57]. The ability to read absorbance of 96 well plates 
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via a Biotek Hl fluorescent plate reader in lab made the ELISA option the most cost 
effective and least time consuming option. The cloning of the N and C-terminal 
tagged expression vectors was performed in the hopes of utilizing them for this 
purpose. However, their inherent cytotoxicity necessitated the use of VSV g-tagged 
MCHRl. Previous experiments designed by our lab to measure MCHRl 
internalization utilizing a cell based ELISA had proven unsuccessful. Controls 
treated with vehicle showed that the apparent internalization of the MCHRl wasn't 
due to endocytosis but rather the VSV g antibodies rate of dissociation from the VSV g 
peptide tag being too great to allow meaningful measurement. 
In an effort to decrease the Kct of the VSV g antibody-antigen complex, several 
methodological variations were performed to the assay. When the protocol for the 
ELISA was initially developed, stably-expressing VSV g-MCHRl CHO cells were 
utilized. In an effort to increase MCHRl expression, transiently-transfected BHK 
cells were used. The protocol was additionally modified by performing the hormone 
time course prior to treatment with primary antibody and by modifying the fixation 
steps by altering the concentrations of paraformaldehyde used to between 2 and 4%. 
The twenty minute blocking step with and goat serum was also removed from 
the original protocol and the 40 minute incubation period with goat anti rabbit HRP 
secondary was performed in PBS without a blocker instead of RIP A with 5% goat 
serum. Unfortunately, all of the modifications that were made to the procedure didn't 
enhance the outcome of the assay with the signal from the receptor remaining at or 
near background. 
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Examining the literature allowed for the discovery of a modified cell based 
ELISA technique optimized by the Hinkle lab at the University of Rochester [58,67]. 
This ELISA protocol utilized a 2 hour incubation period in buffered media containing 
primary mouse anti VSV g antibody, treatment with hormone, fixation in 3% 
paraformaldehyde, and then treatment with secondary antibody. ELISA's performed 
with this procedure produced signal to background ratios of 5: 1 or greater. As to why 
this procedure worked while the others previously performed didn't is a good 
question. It is possible the cells maintained a more homeostatic atmosphere while 
being treated with antibody at room temp in buffered media allowing for better 
antibody binding than when antibody was in RIP A or PBS at room temp as opposed 
to 4 °C. It is also possible that fixing the cells in 3% paraformaldehyde after primary 
antibody treatment fixed the antibody to the receptors and therefore the cells through 
protein cross linking. To verify the protocol was functional, controls were performed 
utilizing a mock time course treating with vehicle. The results were positive and 
verified only a± 5% variation after 30 minutes. 
Had the modified not worked, several other variations to the protocol 
could have been performed. It v10uld be possible to eliminate the entire secondary 
antibody and POD blue section of the protocol by utilizing fluorescently tagged IgG 
primary antibodies. Such tagging kits are readily available from companies such as 
Invitrogen and covalently link fluorescent dies to the IgG antibodies [ 67]. Another 
option would be to produce monoclonal antibodies to the MCHRl and MCHR2 
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receptors themselves through the formation of a hybridoma cell line. This would 
allow the specific targeting of extracellular regions of the receptor. 
MCHRl Internalization 
The desensitization of MCHRl was first described by Lembo et al., who 
observed internalization of MCHRl through fluorescent microscopy following 
agonist treatment [ 68]. Subsequent studies by the labs of Evans et al. and Saito et al. 
attempted to characterize MCHRl internalization in respect to the~ -arrestin and 
clathrin-mediated pathway. Saito measured MCHRl internalization in stably 
transfected HEK293T cells via flow cytometry and fluorescence microscopy. Their 
results showed that the concentration of Flag tagged MCHRl located on the plasma 
membrane fell by 44.2% after 30 minutes of agonist treatment [56]. Our ELISA data 
indicated a 15% decrease of receptor on the plasma membrane after 30 minutes. 
There could be several reasons for the discrepancy in the rate of 
internalization of MCHRl. Saito et al. used HEK293 cells for their experiments [56] 
while the ELISA utilized BHK570 cells. There could be differential levels in the 
expression of MCHRl as well as accessory proteins involved in endocytosis betvveen 
the cell types. This hypothesis is further supported by the fact that the HEK293 cells 
line was a stable transfection where as the BHK570 line was a transient transfection. 
The stable transfection would require random recombination into the cellular genome 
which could interfere with endogenous protein expression altering the results. The 
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number of plasmids in a transiently-transfected cell is also generally much greater 
than a stably-transfected cell further altering the expression levels. 
The clathrin-mediated endocytosis pathway has been widely characterized 
from studies of other GPCRs [69]. The~ -arrestins are an important mediator of this 
pathway, helping to recruit clathrin heavy chain to the receptor [29]. Other GPCR's 
such as the ~2 adrenergic receptor are known to desensitize through this pathway [70]. 
Saito further studied this potential method of MCHRI desensitization by co-
transfecting stably expressing HEK293 cells with both dominant negative~ -arrestin 
I and dominant negative ~-arrestin 2 and measuring receptor internalization [56]. A 
dominant-negative mutation is a mutant form of a protein, in this case ~-arrestin I and 
2, that prevents its proper function while at the same time inhibits the expression of 
wild-type protein [71]. According to their findings, the expression of dominant 
negative ~-arrestin 1 had no effect on the rate of MCHRl internalization. Co-
transfection with dominant-negative ~-arrestin 2 resulted in a 38% reduction in the 
number of receptors undergoing endocytosis suggesting only ~-arrestin 2 plays a role 
in MCHRl endocytosis [56]. 
Based on the assertion that dominant negative ~ -arrestins would knock down 
normal function of~ -arrestins thus interfering with internalization and that the over 
expression of wild type ~ -arrestin would be expected to enhance receptor 
internalization, it would be expected that over expression of~ -arrestin 2 would 
increase MCHRl internalization while ~-arrestin I would have no effect. The ELISA 
results for BHK570 cells cotransfected with VSV g MCHRl and either ~ -arrestin I or 
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0-arrestin 2, both showed a significant increase in the level of agonist mediated 
internalization while 0-arrestin I showed evidence of agonist independent. This 
directly contradicts the previous findings on 0 -arrestin 1 [ 56]. 
The increase in the rate of MCHRI desensitization due to 0 -arrestin 2 over 
expression is consistent with Saito's finding with dominant negative 0 -arrestin 2. 
What is interesting is that HEK293T cells transiently overexpressing wild type 0 -
arrestin 2 showed no significant change in the rate ofreceptor internalization [57]. 
This suggests that the transfection may have not been successful or that the ~ -arrestin 
2 cDNA may have been degraded to a point making it nonfunctional. The significant 
differences in the 0 -arrestin I results point toward the possibility of a cell type 
specific mechanism of receptor internalization, where the rate and method of MCHRI 
internalization is mediated by the expression levels of accessory proteins in each 
individual cell type. 
The protein kinase GRK2 is known to phosphorylate serine threonine residues 
on the third intracellular loop and C-terminal tail of GPCRs increasing their affinity 
for 0 -arrestins in a agonist dependant manner [23]. The affect of GRK2 over 
expression on the desensitization of MCHRl had yet to be explicitly measured 
although Evans et al. utilized GRK2 transfected cells while observing the nature of 
the interaction of 0 -arrestins with MCHRI [56]. The ELISA results indicated that 
over expression of GRK2 enhanced the agonist induced internalization of MCHRI, 
though to a lesser extent than cells expressing 0 -arrestin I or 2. These results mirror 
those from a previous study done with 02 adrenergic receptor [72]. The 02 adrenergic 
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receptor study went further and triple transfected B2 adrenergic receptor, B2 adrenergic 
receptor kinase, and B-arrestins showing a significant synergistic effect. This would 
suggest that the rate-limiting step in receptor desensitization, at least for fo adrenergic 
receptor, is dependent on the cellular concentration of 0-arrestins. It is also possible 
that the phosphorylation of the C-terminal tail and third intracellular loop is not an 
explicit requirement for MCHRI internalization. 
There was also evidence of agonist-independent internalization with GRK2 
over expression. The results from the 0 -arrestin 1 ELISA suggested that B -arrestin 1 
could mediate agonist-independent endocytosis and the BHK570 cells would natively 
express 0 -arrestin 1 at endogenous levels. What is unclear is why GRK2 enhanced 
this pathway since it functions in an agonist-dependant manner. Agonist-independent 
regulation of GPCRs by GRK2 has been previously reported but generally involves 
regulation of the G proteins through their sequestration and not receptor 
internalization [73]. 
The transient over expression of dominant-negative GRK2 significantly 
inhibited MCHRI internalization in response to agonist treatment. Agonist-induced 
internalization of MCHR.1 vvhile overexpressing dominant negative GRK 2 showed 
no significant increase in the rate of receptor internalization. These findings were 
similar to the µ-opioid receptors, which are dependent on phosphorylation by GRKs 
for the recruitment of B-arrestins and contrast that of the 02 adrenergic receptor, 
which can interact with 0-arrestins in the absence of GRK2 phosphorylation sites 
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[74,75]. This suggests that MCHRl is dependent on GRK2 phosphorylation for the 
recruitment of 0-arrestins. 
We also observed the interaction between VSVg-MCHRl and 0 -arrestin 1 
and 2. Evans et al. observed the interaction between the 0 -arrestins and MCHRl 
through confocal microscopy. Both 0 -arrestin 1 and 0 -arrestin 2 were tagged with 
GFP and transiently co-transfected with GRK2 into HEK293T cells stably expressing 
MCHRl. Their results showed that treatment with MCH didn't result in any 
appreciable co localization of 0 -arrestin 1 GFP with MCHRl at the cells surface. 
MCH treatment of cells expressing 0 -arrestin 2 GFP however resulted in fluorescent 
foci at the plasma membrane of the cells with some evidence of internalization 
through the visualization of punctate vesicles within the cell. Prolonged hormone 
treatment showed no increase in the number of fluorescent vesicles internalized into 
the cell [ 56]. 
The fluorescent microscopy results for 0 -arrestin 2 mirrored those previously 
described. However, the fluorescence microscopy of 0 -arrestin 1 suggested its 
affinity for MCHRl was similar to that of 0 -arrestin contradicting previous 
findings with colocalized fluorescence following agonist treatment. The findings 
strongly suggest that MCHRl may be a hybrid receptor that has characteristics of 
both Class A and Class B GPCRs. The Class A family of GPCRs is characterized by 
the dissociation of 0 -arrestin 1 and 2 from the receptor prior to endocytosis and the 
rapid recycling of the receptor back to the plasma membrane. Class A receptors 
affinity toward 0 -arrestin 2 is also greater than their affinity toward 0 -arrestin 1 [31]. 
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This preferential affinity wasn't observed for VSV g MCHRI which is characteristic 
of Class B receptors. 
CONCLUSIONS 
The aims of this thesis included creating epitope-tagged expression vectors for 
both MCHRI and MCHR2, characterizing their interaction with GRK2, 0-arrestin 1, 
and 0-arrestin 2, and to visualize if MCHRI and MCHR2 are colocalized at the 
plasma membrane when coexpressed. The N-terminal epitope tagging of both 
MCHRI and MCHR2 were plagued with cell cytotoxicity issues. Whether these 
issues were a result of a conformational shift to the receptors impeding their transport 
to the plasma membrane and subsequent accumulation in the cytoplasm and cellular 
organelles or the result of overexpression due to too strong of a promoter, we were 
unable to satisfactorily express protein in any cells transfected. Both N-terminal and 
C-terminal epitope tagging of MCHRI has been performed successfully in the past 
with the creation of C-terminal eYFP tagged MCHRI and N-terminal tagged VSVg 
MCHRI and Flag tagged MCHRI [56,66]. It would be interesting to create vectors 
with inducible promoters to see if the cytotoxicity issues could be minimized while 
still producing a strong level of expression. 
The agonist-induced desensitization of GPCR's has been widely characterized. 
Desensitization studies of MCHRI had been previously performed but the results 
reported were somewhat contradictory [55,56,68]. The results from the ELISAs 
indicate that MCHRI doesn't readily internalize when exposed to agonist. The 
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overexpression of GRK2, 0-arrestin 1 and 0-arrestin 2 assisted in desensitization but 
the percentage ofMCHRl sequestered was never above 40% in any case. The 
interaction between MCHRI and 0-arrestins seemed to be transient suggesting the 
receptor would be more readily recycled to the membrane rather than degraded. 
Examining the literature of other GPCRs, such as 02-adrenergic receptor, 
gonadotropin-releasing hormone receptor, µ opioid and 8 opioid receptors, show that 
the level of sequestration is dependent on the receptor itself, the ligand binding to it if 
the receptor has multiple agonists, and the cell type the receptor is expressed in 
[54,72,76,77]. 
It is likely that the differences in receptor sequestering in various types of 
cells is due to differential expression of proteins such as GRK's and 0-arrestins. It 
would be interesting to triple transfect cells with MCHRI, GRK2, and 0-arrestin and 
measure the percentage of receptor sequestered to see if there is a difference. Any 
such differences suggest that MCH-mediated signaling and its affects are regulated in 
a cell type specific manner. It is also possible MCHRI is desensitized in a clathrin-
independent manner. rafts on the plasma membrane been shown to be 
enriched in MCHRl and could potentially be involved signal mediation [61]. 
Although further experimentation needs to be performed, such as measuring 
MCHRl desensitization over time based on its signal to leptin, it is possible to form a 
hypothesis on MCHRl desensitization based on the results from the ELISA's. In this 
model, MCHRI is localized in lipid rafts. Under agonist exposure, it is sequestered in 
a clathrin-dependent manner where it is internalized and rapidly recycled back to the 
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plasma membrane. It is possible that there are as of yet unknown compartments 
within the cell holding native receptor that replenish MCHRI on the plasma 
membrane under agonist exposure. This would explain the up regulation of MCHRl 
on the cell surface when cells expressing dominant negative GRK2 were treated with 
agonist. Receptor up regulation has been previously reported in other receptors in 
response to agonist treatment [78]. 
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APPENDIX 
1 
Primer Name Sequence 5' - 3' Tm(°C) 
Jay's MCHRl No Stop Up GCC CGA ATT CTA TCA GTG GGA GCC AT 63.6 
MCHRl Xho Down GCC AGT CAG GTG CCT TTG 60.6 
Jay's MCHR2 No Stop Up GCC CGA ATT CTA AAT CCA TTT CAT GC 59.4 
MCHR2 Xho Down GCC AGT CAA AAG TGT GTG ATT TC 58.3 
MCHRl UpNhe 
MCHRl Down Xho 
MCHR2 UpNhe 
MCHR2 Down Xho 
GTA TAC CAT GTC AGT GGG AG 
TCTAGA TAAGGTGCCTTTGC 
GTA AGCTACCATGAATCCATTTC 
TCT AGA CAA AAA GTG TGA TT 
77 
64 
63 
60.2 
60.5 
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